Your browser doesn't support javascript.
loading
New method to differentiate between lupus anticoagulants, progressive coagulation inhibitors and coagulation factor deficiencies in the mixing tests.
Shimomura, Daiki; Kumano, Osamu; Ueda, Kaori; Kitano, Keisuke; Arai, Nobuo; Shimada, Masashi; Kamioka, Mikio.
Affiliation
  • Shimomura D; Department of Laboratory Medicine, Tenri Hospital, Tenri, Japan.
  • Kumano O; Protein technology, Department of Reagent engineering, Sysmex Corporation, Kobe, Japan.
  • Ueda K; Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Takamatsu, Japan.
  • Kitano K; Osaka Branch, Sysmex Corporation, Osaka, Japan.
  • Arai N; Protein technology, Department of Reagent engineering, Sysmex Corporation, Kobe, Japan.
  • Shimada M; Protein technology, Department of Reagent engineering, Sysmex Corporation, Kobe, Japan.
  • Kamioka M; Department of Laboratory Medicine, Tenri Hospital, Tenri, Japan.
Int J Lab Hematol ; 2024 Apr 21.
Article in En | MEDLINE | ID: mdl-38644054
ABSTRACT

INTRODUCTION:

Mixing tests in activated partial thromboplastin time (APTT) are used for the differentiation between lupus anticoagulants (LA), coagulation inhibitors, and factor deficient samples with APTT prolongation. However, the indexes for the differentiation have not been established. The present study aimed to develop new mixing test indexes for the differentiation.

METHODS:

Twenty-six LA-positive, 8 progressive coagulation factor VIII inhibitor, and 35 coagulation deficient samples were employed. APTT were measured for normal plasma, patient plasma, and mixing plasma prepared at a ratio of 11 proportion in both without incubation and 2 h-incubation. New two parameters named as ALD50 and mixture plasma-patient plasma after Warming change rate Subtraction (WaS) calculated from the clotting times of normal, 11 mixing and patient samples with/without 2 h-incubation were established. In the samples with WaS result of <10.2%, ALD50 of ≥87.8%, and < 87.8% were defined as LA and coagulation factor deficiency, respectively, and WaS of ≥10.2% defined progressive coagulation factor inhibitors.

RESULTS:

Sensitivity and specificity to LA were 80.8% and 93.0% for ALD50, and sensitivity and specificity to progressive coagulation factor inhibitor were 100.0% and 100.0% for WaS, respectively. The agreement between sample classification and WaS-ALD50 was 88.4% (61/69).

CONCLUSIONS:

ALD50 and WaS showed acceptable sensitivity and specificity to LA and progressive coagulation factor inhibitor, respectively. These indexes would be useful for the differentiation between LA, factor deficiency, and progressive coagulation factor inhibitor in the mixing tests.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int J Lab Hematol Journal subject: HEMATOLOGIA Year: 2024 Type: Article Affiliation country: Japan

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int J Lab Hematol Journal subject: HEMATOLOGIA Year: 2024 Type: Article Affiliation country: Japan